- Home
- PRLD vs OTLK Comparison
PRLD vs OTLK Comparison
Compare PRLD & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- OTLK
- Stock Information
- Founded
- PRLD 2016
- OTLK 2010
- Country
- PRLD United States
- OTLK United States
- Employees
- PRLD N/A
- OTLK N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRLD Health Care
- OTLK Health Care
- Exchange
- PRLD Nasdaq
- OTLK Nasdaq
- Market Cap
- PRLD 48.6M
- OTLK 48.3M
- IPO Year
- PRLD 2020
- OTLK 2016
- Fundamental
- Price
- PRLD $0.82
- OTLK $2.01
- Analyst Decision
- PRLD Strong Buy
- OTLK Strong Buy
- Analyst Count
- PRLD 2
- OTLK 5
- Target Price
- PRLD $4.50
- OTLK $9.60
- AVG Volume (30 Days)
- PRLD 121.2K
- OTLK 877.0K
- Earning Date
- PRLD 08-11-2025
- OTLK 08-13-2025
- Dividend Yield
- PRLD N/A
- OTLK N/A
- EPS Growth
- PRLD N/A
- OTLK N/A
- EPS
- PRLD N/A
- OTLK 0.83
- Revenue
- PRLD $7,000,000.00
- OTLK N/A
- Revenue This Year
- PRLD N/A
- OTLK N/A
- Revenue Next Year
- PRLD N/A
- OTLK $419.06
- P/E Ratio
- PRLD N/A
- OTLK $2.47
- Revenue Growth
- PRLD N/A
- OTLK N/A
- 52 Week Low
- PRLD $0.61
- OTLK $0.87
- 52 Week High
- PRLD $6.80
- OTLK $8.32
- Technical
- Relative Strength Index (RSI)
- PRLD 44.66
- OTLK 51.30
- Support Level
- PRLD $0.81
- OTLK $1.92
- Resistance Level
- PRLD $1.00
- OTLK $2.14
- Average True Range (ATR)
- PRLD 0.08
- OTLK 0.16
- MACD
- PRLD 0.00
- OTLK -0.03
- Stochastic Oscillator
- PRLD 20.48
- OTLK 16.87
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.